Gilead Sciences (GILD) Proxy filing summary

Executive summary

• Annual meeting scheduled for April 30, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote on key proposals before April 29, 2026.

Voting matters and shareholder proposals

• Election of nine director nominees for a one-year term, with all nominees recommended by the board.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote to approve executive compensation as presented.

• Approval sought for amended and restated 2022 Equity Incentive Plan.

• Stockholder proposals include: independent Board Chair policy, report on extended patent exclusivities' impact on patient access, and report on risks of ESG and DEI executive compensation metrics; board recommends voting against all three.

Board of directors and corporate governance

• Nine director nominees listed, including individuals with diverse backgrounds in science, medicine, and business.

• Board recommends all nominees for election.